Panlong Pharmaceutical released its 2026 interim report, with total operating revenue of 423 million yuan, down 26.38% year on year, and net profit attributable to the parent of 42.3761 million yuan, down 29.53% from the same period last year. Net cash inflow from operating activities was 177 million yuan, the asset-liability ratio was 25.97%, gross margin was 57.72%, ROE was 2.44%, and diluted earnings per share was 0.31 yuan. The company had 19,300 shareholders, and the top ten shareholders held 41.59% of the total share capital.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class ANet profit fell 29.53% and revenue declined 26.38% in the interim report.
